Triglav Investments D.O.O. Sells 99,092 Shares of Pfizer Inc. $PFE

Triglav Investments D.O.O. reduced its stake in Pfizer Inc. (NYSE:PFE) by 23.8% during the first quarter, according to its most recent filing with the SEC. The fund owned 316,700 shares of the biopharmaceutical company’s stock after selling 99,092 shares during the quarter. Triglav Investments D.O.O.’s holdings in Pfizer were worth $8,893,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in PFE. Vermillion Wealth Management Inc. boosted its stake in Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 382 shares during the last quarter. Triad Wealth Partners LLC increased its stake in shares of Pfizer by 1.9% during the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 386 shares during the last quarter. Eagle Capital Management LLC lifted its stake in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after purchasing an additional 390 shares during the last quarter. ETF Store Inc. grew its holdings in Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares during the period. Finally, Mattern Wealth Management LLC increased its position in Pfizer by 4.6% in the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.2%

Shares of Pfizer stock opened at $24.21 on Monday. The company’s 50-day moving average price is $25.37 and its 200-day moving average price is $26.19. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a market cap of $138.01 billion, a price-to-earnings ratio of 18.48 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the business earned $0.92 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is presently 131.30%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on PFE shares. Morgan Stanley increased their price target on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. CICC Research assumed coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target on the stock. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research note on Tuesday, June 23rd. Finally, Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.56.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer, expanding the label for a key Pfizer/Astellas regimen and potentially opening the door to more sales in oncology. Article: U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
• Positive Sentiment: Pfizer’s oncology story also got incremental attention from a completed lorlatinib lung cancer study and other clinical updates, which keep investors focused on the company’s pipeline rather than only its mature products. Article: Pfizer’s Lorlatinib Lung Cancer Study Wraps Up, Offering Fresh Signals for PFE Investors
• Neutral Sentiment: Bank of America lowered its price target on Pfizer to $26 from $27 while keeping a neutral rating, signaling limited upside but no major change in its overall stance. Article: Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00.
• Negative Sentiment: Several market commentary pieces highlighted concerns about Pfizer’s growth outlook and mixed second-quarter expectations, including skepticism about how quickly Seagen-related benefits will show up in results. Article: Pfizer Poised for Mixed Second Quarter, RBC Says

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.